Ginkgo Bioworks Holdings (DNA) Short term Debt (2020 - 2021)
Ginkgo Bioworks Holdings (DNA) posted Short term Debt of $631638.0 for Q2 2021, up 304.03% on a QoQ basis from $156333.0 in Q4 2020.
Ginkgo Bioworks Holdings (DNA) Short term Debt (2020 - 2021) Analysis & Trends
Ginkgo Bioworks Holdings' Short term Debt history runs 2 years deep, the most recent figure standing at $631638.0 for Q2 2021.
- Quarterly Short term Debt changed N/A year-over-year to $631638.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $631638.0 (changed N/A YoY) and the FY2020 annual result came in at $156333.0, changed N/A from the prior year.
- Short term Debt was $631638.0 for Q2 2021 at Ginkgo Bioworks Holdings, up from $156333.0 in the prior quarter.
- Across five years, Short term Debt topped out at $631638.0 in Q2 2021 and bottomed at $156333.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 631,638.00 |
| Dec 31, 2020 | 156,333.00 |